866-997-4948(US-Canada Toll Free)

Sarcomas Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 177 Pages


Sarcomas Pipeline Review, H2 2012

Global Markets Directs, 'Sarcomas Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Sarcomas.
  • A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Sarcomas.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Sarcomas Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Sarcomas 12
Sarcomas Therapeutics under Development by Companies 14
Sarcomas Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Pre-Clinical Stage Products 29
Comparative Analysis 29
Sarcomas Therapeutics – Products under Development by Companies 30
Sarcomas Therapeutics – Products under Investigation by Universities/Institutes 34
Companies Involved in Sarcomas Therapeutics Development 48
Bristol-Myers Squibb Company 48
Genzyme Corporation 49
Johnson & Johnson 50
F. Hoffmann-La Roche Ltd. 51
Amgen Inc. 52
Sanofi-Aventis 53
Eli Lilly and Company 54
GlaxoSmithKline plc 55
Merck & Co., Inc. 56
Gamida Cell Ltd. 57
Infinity Pharmaceuticals, Inc. 58
Delcath Systems, Inc. 59
Prolexys Pharmaceuticals, Inc. 60
ZIOPHARM Oncology, Inc. 61
Auxilium Pharmaceuticals, Inc. 62
Eisai Co., Ltd. 63
Pfizer Inc. 64
Cell Therapeutics, Inc. 65
Menarini Group 66
Alchemia Limited 67
Celldex Therapeutics, Inc. 68
AEterna Zentaris Inc. 69
Cleveland BioLabs, Inc. 70
Oncolytics Biotech Inc. 71
National Cancer Institute (NCI) 72
ARQULE, INC 74
TopoTarget A/S 75
CytRx Corporation 76
Pharmacyclics, Inc. 77
Threshold Pharmaceuticals, Inc. 78
MabVax Therapeutics, Inc. 79
Nanobiotix 80
Morphotek, Inc. 81
PCI Biotech Holding ASA 82
Philogen S.p.A. 83
Azaya Therapeutics, Inc. 84
GP Pharm, S.A. 85
S*BIO Pte Ltd 86
Neotropix, Inc. 87
Axelar AB 88
MolMed S.p.A. 89
Cellceutix Corporation 90
PharmaMar, S.A. 91
Polaris Group 92
Epeius Biotechnologies Corporation 93
Sarcomas – Therapeutics Assessment 94
Assessment by Monotherapy Products 94
Assessment by Combination Products 95
Assessment by Route of Administration 96
Assessment by Molecule Type 98
Drug Profiles 100
eribulin mesylate - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ombrabulin - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
palifosfamide - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
trabectedin - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Rexin-G - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
paclitaxel - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 112
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 114
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Ombrabulin + Cisplatin - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Ifosfamide + Paclitaxel - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
palifosfamide + doxorubicin - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
TH-302 + Doxorubicin - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
ifosfamide - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Trofosfamide + Idarubicin + Etoposide - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Filgrastim + Doxorubicin + Ifosfamide + Radiation Therapy - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Gemcitabine + Docetaxel - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Doxorubicin + Ifosfamide - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
trabectedin - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
bevacizumab + filgrastim + pegfilgrastim + docetaxel + gemcitabine hydrochloride - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 134
Dactinomycin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Mesna + Vincristine Sulfate - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 137
Doxorubicin  + Ifosfamide + Radiation Therapy - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
trabectedin - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Adriamycin + Vindesine - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Sarcomas Therapeutics – Drug Profile Updates 143
Sarcomas Therapeutics – Discontinued Products 154
Sarcomas Therapeutics - Dormant Products 156
Sarcomas – Product Development Milestones 170
Featured News & Press Releases 170
Oct 03, 2012: TopoTarget Announces Phase I/II Clinical Trial Results Of Belinostat In Combination With Doxorubicin In Soft Tissue Sarcoma 170
Sep 07, 2012: CytRx Announces Presentation Of Phase Ib/II Clinical Trial Results Of Aldoxorubicin At Preeminent Sarcoma Conference 170
Aug 27, 2012: Morphotek Initiates MORAb-004 Phase II Study In Metastatic Soft Tissue Sarcoma 171
Aug 07, 2012: CytRx Announces Presentation Of Aldoxorubicin Clinical Data At ESMO 2012 Congress 171
Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib 172
Aug 02, 2012: Ziopharm Receives News US Patent For Palifosfamide 173
Aug 01, 2012: Independent Data Monitoring Committee Of Ziopharm's Phase III Study Of Palifosfamide Recommends Continuation Of Trial Following Planned Interim Futility Analysis 173
Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says 173
Jul 02, 2012: CytRx Announces Issuance Of European Patent Covering INNO-206 Linker Technology 174
Jun 26, 2012: BioSpecifics Initiates XIAFLEX Phase II Trial For Human Lipomas 175

Appendix 176
Methodology 176
Coverage 176
Secondary Research 176
Primary Research 176
Expert Panel Validation 176
Contact Us 177
Disclaimer 177

List of Table


Number of Products Under Development for Sarcomas, H2 2012 12
Products under Development for Sarcomas Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Development by Companies, H2 2012 (Contd..2) 17
Number of Products under Development by Companies, H2 2012 (Contd..3) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 25
Comparative Analysis by Late Stage Development, H2 2012 26
Comparative Analysis by Mid Clinical Stage Development, H2 2012 27
Comparative Analysis by Early Clinical Stage Development, H2 2012 28
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Development by Companies, H2 2012 (Contd..1) 31
Products under Development by Companies, H2 2012 (Contd..2) 32
Products under Development by Companies, H2 2012 (Contd..3) 33
Products under Investigation by Universities/Institutes, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 47
Bristol-Myers Squibb Company, H2 2012 48
Genzyme Corporation, H2 2012 49
Johnson & Johnson, H2 2012 50
F. Hoffmann-La Roche Ltd., H2 2012 51
Amgen Inc., H2 2012 52
Sanofi-Aventis, H2 2012 53
Eli Lilly and Company, H2 2012 54
GlaxoSmithKline plc, H2 2012 55
Merck & Co., Inc., H2 2012 56
Gamida Cell Ltd., H2 2012 57
Infinity Pharmaceuticals, Inc., H2 2012 58
Delcath Systems, Inc., H2 2012 59
Prolexys Pharmaceuticals, Inc., H2 2012 60
ZIOPHARM Oncology, Inc., H2 2012 61
Auxilium Pharmaceuticals, Inc., H2 2012 62
Eisai Co., Ltd., H2 2012 63
Pfizer Inc., H2 2012 64
Cell Therapeutics, Inc., H2 2012 65
Menarini Group, H2 2012 66
Alchemia Limited, H2 2012 67
Celldex Therapeutics, Inc., H2 2012 68
AEterna Zentaris Inc., H2 2012 69
Cleveland BioLabs, Inc., H2 2012 70
Oncolytics Biotech Inc., H2 2012 71
National Cancer Institute (NCI), H2 2012 72
ARQULE, INC, H2 2012 74
TopoTarget A/S, H2 2012 75
CytRx Corporation, H2 2012 76
Pharmacyclics, Inc., H2 2012 77
Threshold Pharmaceuticals, Inc., H2 2012 78
MabVax Therapeutics, Inc., H2 2012 79
Nanobiotix, H2 2012 80
Morphotek, Inc., H2 2012 81
PCI Biotech Holding ASA, H2 2012 82
Philogen S.p.A., H2 2012 83
Azaya Therapeutics, Inc., H2 2012 84
GP Pharm, S.A., H2 2012 85
S*BIO Pte Ltd, H2 2012 86
Neotropix, Inc., H2 2012 87
Axelar AB, H2 2012 88
MolMed S.p.A., H2 2012 89
Cellceutix Corporation, H2 2012 90
PharmaMar, S.A., H2 2012 91
Polaris Group, H2 2012 92
Epeius Biotechnologies Corporation, H2 2012 93
Assessment by Monotherapy Products, H2 2012 94
Assessment by Combination Products, H2 2012 95
Assessment by Stage and Route of Administration, H2 2012 97
Assessment by Stage and Molecule Type, H2 2012 99
Sarcomas Therapeutics Drug Profile Updates 143
Sarcomas Therapeutics Discontinued Products 154
Sarcomas Therapeutics Discontinued Products (Contd..1) 155
Sarcomas Therapeutics Dormant Products 156
Sarcomas Therapeutics Dormant Products (Contd..1) 157
Sarcomas Therapeutics Dormant Products (Contd..2) 158
Sarcomas Therapeutics Dormant Products (Contd..3) 159
Sarcomas Therapeutics Dormant Products (Contd..4) 160
Sarcomas Therapeutics Dormant Products (Contd..5) 161
Sarcomas Therapeutics Dormant Products (Contd..6) 162
Sarcomas Therapeutics Dormant Products (Contd..7) 163
Sarcomas Therapeutics Dormant Products (Contd..8) 164
Sarcomas Therapeutics Dormant Products (Contd..9) 165
Sarcomas Therapeutics Dormant Products (Contd..10) 166
Sarcomas Therapeutics Dormant Products (Contd..11) 167
Sarcomas Therapeutics Dormant Products (Contd..12) 168
Sarcomas Therapeutics Dormant Products (Contd..13) 169

List of Chart


Number of Products under Development for Sarcomas, H2 2012 12
Products under Development for Sarcomas Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 26
Mid Clinical Stage Products, H2 2012 27
Early Clinical Stage Products, H2 2012 28
Pre-Clinical Stage Products, H2 2012 29
Assessment by Monotherapy Products, H2 2012 94
Assessment by Combination Products, H2 2012 95
Assessment by Route of Administration, H2 2012 96
Assessment by Stage and Route of Administration, H2 2012 97
Assessment by Molecule Type, H2 2012 98
Assessment by Stage and Molecule Type, H2 2012 99

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *